Related Experiment Video
Updated: Dec 7, 2025

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
Developing an ontology for representing the domain knowledge specific to non-pharmacological treatment for agitation
Zhenyu Zhang1, Ping Yu1,2, Hui Chen Rita Chang2,3
1Centre for Digital Transformation School of Computing and Information Technology University of Wollongong Wollongong New South Wales Australia.
Introduction:
A large volume of clinical care data has been generated for managing agitation in dementia. However, the valuable information in these data has not been used effectively to generate insights for improving the quality of care. Application of artificial intelligence technologies offers us enormous opportunities to reuse these data. For health data science to achieve this, this study focuses on using ontology to coding clinical knowledge for non-pharmacological treatment of agitation in a machine-readable format.
Methods:
The resultant ontology-Dementia-Related Agitation Non-Pharmacological Treatment Ontology (DRANPTO)-was developed using a method adopted from the NeOn methodology.
Results:
DRANPTO consisted of 569 concepts and 48 object properties. It meets the standards for biomedical ontology.
Discussion:
DRANPTO is the first comprehensive semantic representation of non-pharmacological management for agitation in dementia in the long-term care setting. As a knowledge base, it will play a vital role to facilitate the development of intelligent systems for managing agitation in dementia.
Related Concept Videos
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Dementia
The progression of dementia is generally gradual....
Drug Therapy
Antianxiety Medications
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Psychosis: Goals of Pharmacotherapy

